FLT3 as a marker of minimal residual disease: Time to re-think? - Wikidata - awgldk - TriplyDB

FLT3 as a marker of minimal residual disease: Time to re-think?

FLT3 as a marker of minimal residual disease: Time to re-think?

http://www.wikidata.org/entity/Q50921275

about

Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?

P2860

Q48224336-1DBA28CE-B11B-4903-9C6C-885BA4DA791A

P2860

FLT3 as a marker of minimal residual disease: Time to re-think?

http://www.wikidata.org/entity/Q50921275

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

FLT3 as a marker of minimal residual disease: Time to re-think?

@en

FLT3 as a marker of minimal residual disease: Time to re-think?

@nl

type

label

FLT3 as a marker of minimal residual disease: Time to re-think?

@en

FLT3 as a marker of minimal residual disease: Time to re-think?

@nl

prefLabel

FLT3 as a marker of minimal residual disease: Time to re-think?

@en

FLT3 as a marker of minimal residual disease: Time to re-think?

@nl

P1433

Q50921275-D0900D58-C84D-428A-ABE3-7213605D8394

P1476

Q50921275-E983B1F8-266C-4EBB-BF92-5F605A77DC1F

P2093

Q50921275-16A6BE74-AF81-4502-A8BA-699435AF73C5

P2860

Q50921275-20CF4D31-EFCB-43AE-ADDE-B0915EFB5FBD

Q50921275-6AAE70E9-C744-4989-B482-0466C383ED3A

Q50921275-83CE1090-2419-4AAE-BA9E-F2E689688AA5

Q50921275-91B489B6-8A21-4A2F-982F-417AA30C94BA

Q50921275-BADF4E72-40F2-4D15-8A40-D6AF9E5471F0

Q50921275-C38B532D-B5FF-41FC-9422-9C560D0ECA7F

Q50921275-D7F47F3D-9E3F-4CFE-BCB0-B96DB8965FE7

Q50921275-E917C002-8E8C-49F7-B596-81671B2458CF

P304

Q50921275-968DF33D-8466-4E6A-BE47-744663C3A868

P31

Q50921275-99526EAD-9742-4BF7-A458-0E96197ADAE4

P356

Q50921275-BC1F07AE-D09B-4457-B83B-875EA1E46DB3

P433

Q50921275-A7B67349-B8B4-487B-BE2C-5C60326E55E6

P478

Q50921275-20D12FC8-AF85-4B02-B0C2-CD586BAC97DF

P577

Q50921275-4AA6D92A-CD99-4CA1-9D31-B7B988AF0F39

P698

Q50921275-680FE8B6-7618-4944-9281-AF6099460229

P356

P1433

American Journal of Hematology

P1476

FLT3 as a marker of minimal residual disease: Time to re-think?

@en

P2093

Mark Levis

http://www.w3.org/2001/XMLSchema#string

P2860

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Assessment of Minimal Residual Disease in Standard-Risk AML.

The origin and evolution of mutations in acute myeloid leukemia

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

P304

329-330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24667

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28142203

http://www.w3.org/2001/XMLSchema#string